Premium
Clarification of the Australian heart failure guideline recommendation for primary prevention defibrillator implantation in non‐ischaemic cardiomyopathy
Author(s) -
Kistler Peter M,
Atherton John J,
Jennings Garry
Publication year - 2020
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja2.50551
Subject(s) - guideline , medicine , primary prevention , cardiology , heart failure , cardiomyopathy , secondary prevention , ischaemic heart disease , intensive care medicine , disease , pathology
The 2018 guidelines from the National Heart Foundation and the Cardiac Society of Australia and New Zealand provide evidencebased direction for the management of heart failure in Australia.1 A Perspective article published in the Journal in 20192 challenged the weak recommendation for the implantation of a defibrillator in the primary prevention of mortality in dilated cardiomyopathy (DCM) with a left ventricular ejection fraction (LVEF) of 35% or below.1 The authors of the MJA article2 questioned the differences between this recommendation1 and recent Canadian and American guidelines.3,4 We welcome this opportunity to clarify the basis for the Australian guidelines recommendation.